scholarly journals Erratum to 'Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial' [European Heart Journal 2003; 24(8): 717–728]

2003 ◽  
Vol 24 (14) ◽  
pp. 1381
Author(s):  
L Melani
Keyword(s):  
European Heart Journal ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Primary Hypercholesterolemia ◽  
Blind Trial

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

2002 ◽  
Vol 162 (2) ◽  
pp. 373-379 ◽  
Author(s):  
Yasushi Saito ◽  
Nobuhiro Yamada ◽  
Tamio Teramoto ◽  
Hiroshige Itakura ◽  
Yoshiya Hata ◽  
...  
Keyword(s):  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Primary Hypercholesterolemia ◽  
Blind Trial

Corrigendum to “A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia”

2003 ◽  
Vol 168 (2) ◽  
pp. 401-402
Author(s):  
Yasushi Saito ◽  
Nobuhiro Yamada ◽  
Tamio Teramoto ◽  
Hiroshige Itakura ◽  
Yoshiya Hata ◽  
...  
Keyword(s):  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Primary Hypercholesterolemia ◽  
Blind Trial

S601 EFFICACY AND SAFETY OF A SUBCUTANEOUS DICLOFENAC FORMULATION IN THE MANAGEMENT OF ACUTE PAIN: A RANDOMISED, DOUBLE-BLIND TRIAL

2011 ◽  
Vol 5 (S1) ◽  
pp. 269-270
Author(s):  
T. Dietrich ◽  
R. Leeson ◽  
B. Zielińska-Kaźmierska ◽  
M. Opadczuk ◽  
E. Kozieł ◽  
...  
Keyword(s):  
Acute Pain ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients

1997 ◽  
Vol 171 (1) ◽  
pp. 73-77 ◽  
Author(s):  
I. Pelc ◽  
P. Verbanck ◽  
O. Le Bon ◽  
M. Gavrilovic ◽  
K. Lion ◽  
...  
Keyword(s):  
Animal Models ◽  
Alcohol Drinking ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial ◽  
Efficacy Parameters ◽  
Clinical Conditions ◽  
Alcohol Dependent

BackgroundAcamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.MethodIn order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).ResultsFor all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.ConclusionThis study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.

Sign in / Sign up

Export Citation Format

Share Document